INTRODUCTION: Doravirine, a non-nucleoside reverse-transcriptase inhibitor in development for the treatment of patients with human immunodeficiency virus-1 infection, has potential to be used concomitantly in antiretroviral therapy with dolutegravir, an integrase strand transfer inhibitor. The pharmacokinetic interactions between these drugs were therefore assessed. METHODS: Oral formulations of doravirine and dolutegravir were dosed both individually and concomitantly once daily in healthy adults. Twelve subjects (six were male), 23-42 years of age, were enrolled and 11 completed this phase I, open-label, three-period, fixed-sequence study per protocol; one subject was discontinued for a positive cotinine test at admission to period 2. In period 1, dolutegravir 50 mg was administered for 7 days. After a 7-day washout, doravirine 200 mg was dosed for 7 days in period 2, followed (without washout) by both doravirine and dolutegravir simultaneously for 7 days in period 3. Plasma samples were taken to determine dolutegravir and doravirine concentrations. RESULTS: The steady-state concentration 24 h post-dose (C24) of dolutegravir was not substantially altered by co-administration of doravirine multiple doses; area under the plasma concentration-time curve from dosing to 24 h post-dose (AUC0-24), maximum concentration (C max), and C24 geometric mean ratios were 1.36, 1.43, and 1.27, respectively. The pharmacokinetics of doravirine was not affected by multiple doses of dolutegravir (geometric mean ratios: 1.00, 0.98, and 1.06 for AUC0-24, C24, and C max, respectively). Both drugs were generally well tolerated. CONCLUSION: The results of this study demonstrate that concomitant administration of doravirine and dolutegravir in healthy subjects causes no clinically significant alteration in the pharmacokinetic and safety profiles of the two drugs, thereby supporting further evaluation of co-administration of these agents for human immunodeficiency virus-1 treatment.
INTRODUCTION:Doravirine, a non-nucleoside reverse-transcriptase inhibitor in development for the treatment of patients with human immunodeficiency virus-1 infection, has potential to be used concomitantly in antiretroviral therapy with dolutegravir, an integrase strand transfer inhibitor. The pharmacokinetic interactions between these drugs were therefore assessed. METHODS: Oral formulations of doravirine and dolutegravir were dosed both individually and concomitantly once daily in healthy adults. Twelve subjects (six were male), 23-42 years of age, were enrolled and 11 completed this phase I, open-label, three-period, fixed-sequence study per protocol; one subject was discontinued for a positive cotinine test at admission to period 2. In period 1, dolutegravir 50 mg was administered for 7 days. After a 7-day washout, doravirine 200 mg was dosed for 7 days in period 2, followed (without washout) by both doravirine and dolutegravir simultaneously for 7 days in period 3. Plasma samples were taken to determine dolutegravir and doravirine concentrations. RESULTS: The steady-state concentration 24 h post-dose (C24) of dolutegravir was not substantially altered by co-administration of doravirine multiple doses; area under the plasma concentration-time curve from dosing to 24 h post-dose (AUC0-24), maximum concentration (C max), and C24 geometric mean ratios were 1.36, 1.43, and 1.27, respectively. The pharmacokinetics of doravirine was not affected by multiple doses of dolutegravir (geometric mean ratios: 1.00, 0.98, and 1.06 for AUC0-24, C24, and C max, respectively). Both drugs were generally well tolerated. CONCLUSION: The results of this study demonstrate that concomitant administration of doravirine and dolutegravir in healthy subjects causes no clinically significant alteration in the pharmacokinetic and safety profiles of the two drugs, thereby supporting further evaluation of co-administration of these agents for human immunodeficiency virus-1 treatment.
Authors: Jan van Lunzen; Franco Maggiolo; José R Arribas; Aza Rakhmanova; Patrick Yeni; Benjamin Young; Jürgen K Rockstroh; Steve Almond; Ivy Song; Cindy Brothers; Sherene Min Journal: Lancet Infect Dis Date: 2011-10-20 Impact factor: 25.071
Authors: Meizhen Feng; Deping Wang; Jay A Grobler; Daria J Hazuda; Michael D Miller; Ming-Tain Lai Journal: Antimicrob Agents Chemother Date: 2014-11-10 Impact factor: 5.191
Authors: Sauzanne Khalilieh; Ka Lai Yee; Rosa I Sanchez; Ilias Triantafyllou; Li Fan; Noha Maklad; Heather Jordan; Maureen Martell; Marian Iwamoto Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191
Authors: Ka Lai Yee; Sauzanne G Khalilieh; Rosa I Sanchez; Rachael Liu; Matt S Anderson; Helen Manthos; Timothy Judge; John Brejda; Joan R Butterton Journal: Clin Drug Investig Date: 2017-07 Impact factor: 2.859
Authors: Sauzanne G Khalilieh; Ka Lai Yee; Rosa I Sanchez; Li Fan; Matt S Anderson; Monali Sura; Tine Laethem; Scott Rasmussen; Luc van Bortel; Griet van Lancker; Marian Iwamoto Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Wendy Ankrom; Rosa I Sanchez; Ka Lai Yee; Li Fan; Pranab Mitra; Dennis Wolford; Ilias Triantafyllou; Laura M Sterling; S Aubrey Stoch; Marian Iwamoto; Sauzanne Khalilieh Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.938
Authors: Deanne Jackson Rudd; Saijuan Zhang; Kerry L Fillgrove; Sabrina Fox-Bosetti; Randolph P Matthews; Evan Friedman; Danielle Armas; S Aubrey Stoch; Marian Iwamoto Journal: Clin Pharmacol Drug Dev Date: 2021-10-22
Authors: Randolph P Matthews; Deanne Jackson Rudd; Kerry L Fillgrove; Saijuan Zhang; Charles Tomek; S Aubrey Stoch; Marian Iwamoto Journal: Clin Drug Investig Date: 2021-06-21 Impact factor: 2.859